New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
10:28 EDTZBRA, VRTX, VSTM, TFM, KPTI, ZINC, HOS, EBKDY, BRKR, BECNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Market Perform from Outperform at William Blair... Bruker (BRKR) downgraded to Neutral from Buy at ISI Group... Erste Group Bank (EBKDY) downgraded to Hold from Buy at Deutsche Bank... Hornbeck Offshore (HOS) downgraded to Equal Weight from Overweight at Stephens... Horsehead Holding (ZINC) downgraded to Market Perform at FBR Capital... Karyopharm (KPTI) downgraded to Perform from Outperform at Oppenheimer... The Fresh Market (TFM) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Perform from Outperform at Oppenheimer... Vertex (VRTX) downgraded to Perform from Outperform at Oppenheimer... Zebra Technologies (ZBRA) downgraded to In-Line from Outperform at Imperial Capital.
News For BECN;BRKR;EBKDY;HOS;ZINC;KPTI;TFM;VSTM;VRTX;ZBRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:51 EDTKPTIKaryopharm management to meet with BofA/Merrill
Subscribe for More Information
06:09 EDTVSTMVerastem presents new data on Mesothelioma programs
Subscribe for More Information
October 22, 2014
05:37 EDTVRTXVertex approval could add 500 more patients, says Piper Jaffray
Subscribe for More Information
October 21, 2014
16:49 EDTVRTXVertex: FDA Advisory Committee recommends approval of KALYDECO
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administrationís Pulmonary Allergy Drugs Advisory Committee voted 13-2 to recommend approval of KALYDECO in people with cystic fibrosis ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory gene, which is the indication being reviewed by the FDA.
15:25 EDTVRTXPanel backs approval for Vertex CF drug in R117H mutation, Bloomberg says
Subscribe for More Information
15:18 EDTVRTXPanel votes Vertex CF drug safe, works for R117H mutation, Bloomberg reports
Subscribe for More Information
07:11 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committe to hold a meeting
Subscribe for More Information
October 17, 2014
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information
October 15, 2014
13:01 EDTZBRAZebra Technologies announces Zatar reseller agreement with GainSpan
Subscribe for More Information
09:12 EDTBECNBeacon Roofing acquires Wholesale Roofing Supply
Subscribe for More Information
07:10 EDTHOSHornbeck Offshore initiated with a Buy at ISI Group
Subscribe for More Information
October 14, 2014
13:59 EDTVRTXVertex mentioned cautiously at BofA/Merrill
October 13, 2014
10:08 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTVRTXVertex price target raised to $131 from $119 at RW Baird
Subscribe for More Information
05:35 EDTVRTXVertex upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Vertex Pharmaceuticals to Overweight citing likely approval of the company's Kalydeco plus lumacaftor combination next year. Piper expects Vertex's Cystic Fibrosis sales to grow to $3.1B in 2016 and raised its price target for shares to $125 from $87.50.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use